Instrumental activities of daily living in neuro-oncology: International validation of the EORTC IADL-BN32 questionnaire.

Brain metastasis Brain tumour Daily functioning Glioma IADL Instrumental activities of daily living

Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
21 Sep 2024
Historique:
received: 12 08 2024
revised: 13 09 2024
accepted: 14 09 2024
medline: 28 9 2024
pubmed: 28 9 2024
entrez: 27 9 2024
Statut: aheadofprint

Résumé

Neurocognitive impairments are common in patients with a brain tumour, and may negatively impact on functioning in daily life, particularly on instrumental activities of daily living (IADL). The EORTC IADL-BN32 questionnaire was developed to measure IADL in this patient population. In this international validation study, we evaluated the EORTC IADL-BN32 questionnaire on several psychometric properties in a large sample of patients with a primary or metastatic brain tumour. We administered the 32-item questionnaire three times: at 'baseline', after 2 weeks and after 3 months. Procedures were in accordance with EORTC Quality of Life Group module development guidelines. In total, 326 patients participated in the study. A bifactor scale structure showed satisfactory model fit measures, with five multi-item scales and two single items, and an IADL sum score. The internal consistency of the multi-item scales ranged from good to excellent (range Cronbach's α: 0.86-0.97). We found significant differences in scale scores between patients with and without neurocognitive impairments or complaints, supporting the construct validity. Initial cross-cultural validity analyses showed indications of item response biases for certain items. Analyses indicated moderate to good test-retest agreement (intraclass correlation coefficient > 0.70) between baseline and the 2-week follow-up assessment for all but one scale. Deterioration of EORTC IADL-BN32 scale scores were consistent with clinically relevant deterioration on other functional measures with small to large effect sizes, however, subgroup sample sizes were small. Overall, the EORTC IADL-BN32 questionnaire exhibited adequate to excellent psychometric properties. Cross-cultural validity and responsiveness should be further explored.

Sections du résumé

BACKGROUND BACKGROUND
Neurocognitive impairments are common in patients with a brain tumour, and may negatively impact on functioning in daily life, particularly on instrumental activities of daily living (IADL). The EORTC IADL-BN32 questionnaire was developed to measure IADL in this patient population.
METHODS METHODS
In this international validation study, we evaluated the EORTC IADL-BN32 questionnaire on several psychometric properties in a large sample of patients with a primary or metastatic brain tumour. We administered the 32-item questionnaire three times: at 'baseline', after 2 weeks and after 3 months. Procedures were in accordance with EORTC Quality of Life Group module development guidelines.
RESULTS RESULTS
In total, 326 patients participated in the study. A bifactor scale structure showed satisfactory model fit measures, with five multi-item scales and two single items, and an IADL sum score. The internal consistency of the multi-item scales ranged from good to excellent (range Cronbach's α: 0.86-0.97). We found significant differences in scale scores between patients with and without neurocognitive impairments or complaints, supporting the construct validity. Initial cross-cultural validity analyses showed indications of item response biases for certain items. Analyses indicated moderate to good test-retest agreement (intraclass correlation coefficient > 0.70) between baseline and the 2-week follow-up assessment for all but one scale. Deterioration of EORTC IADL-BN32 scale scores were consistent with clinically relevant deterioration on other functional measures with small to large effect sizes, however, subgroup sample sizes were small.
CONCLUSION CONCLUSIONS
Overall, the EORTC IADL-BN32 questionnaire exhibited adequate to excellent psychometric properties. Cross-cultural validity and responsiveness should be further explored.

Identifiants

pubmed: 39332215
pii: S0959-8049(24)00991-2
doi: 10.1016/j.ejca.2024.114335
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114335

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Q Oort (Q)

Cancer Center Amsterdam, Brain Tumor Center, Amsterdam, the Netherlands; Department of Neurology & Brain Tumor Center Amsterdam, Amsterdam University Medical Centers (Location VUmc), Amsterdam, the Netherlands.

J C Reijneveld (JC)

Cancer Center Amsterdam, Brain Tumor Center, Amsterdam, the Netherlands; Department of Neurology & Brain Tumor Center Amsterdam, Amsterdam University Medical Centers (Location VUmc), Amsterdam, the Netherlands; Department of Neurology, Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede, the Netherlands.

S A M Sikkes (SAM)

Alzheimer Center, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Vrije Universiteit Amsterdam, Faculty of Behavioural and Movement Sciences (FGB), Department of Clinical Developmental & Clinical Neuropsychology, Amsterdam, the Netherlands.

J A F Koekkoek (JAF)

Department of Neurology, Haaglanden Medical Center, The Hague, the Netherlands; Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.

F Boele (F)

Leeds Institute of Medical Research, St James's University Hospital, Leeds LS9 7TF, United Kingdom; Leeds Institute of Health Sciences, Faculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, United Kingdom.

T Young (T)

East & North Hertfordshire NHS Trust Incorporating Mount Vernon Cancer Centre, Northwood, United Kingdom.

C Brannan (C)

East & North Hertfordshire NHS Trust Incorporating Mount Vernon Cancer Centre, Northwood, United Kingdom.

T Chalk (T)

East & North Hertfordshire NHS Trust Incorporating Mount Vernon Cancer Centre, Northwood, United Kingdom.

A Talacchi (A)

Department of Neurosurgery, Azienda Ospedaliera San Giovanni Addolorata, Roma, Italy.

A Mazzotta (A)

Department of Neurosurgery, Azienda Ospedaliera San Giovanni Addolorata, Roma, Italy.

Y Narita (Y)

Department of Neurosurgery and Neuro-oncology, National Cancer Center Hospital, Tokyo, Japan.

H Sato (H)

Department of Neurosurgery and Neuro-oncology, National Cancer Center Hospital, Tokyo, Japan; Department of Nursing, Teikyo Heisei University, Tokyo, Japan.

Y Miyakita (Y)

Department of Neurosurgery and Neuro-oncology, National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of JFCR, Tokyo, Japan.

O Shamieh (O)

Department of Palliative Medicine, King Hussein Cancer Center (KHCC), Amman, Jordan; School of Medicine, University of Jordan, Amman, Jordan; Center for Palliative & Cancer Care in Conflict (CPCCC), KHCC, Amman, Jordan.

W Alrjoob (W)

Center for Palliative & Cancer Care in Conflict (CPCCC), KHCC, Amman, Jordan.

A Pace (A)

Neuro-Oncology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

D Petranovic (D)

Department of Hematology, Clinical Hospital Center Rijeka, Rijeka, Croatia.

M Ploh (M)

Department of Hematology, Clinical Hospital Center Rijeka, Rijeka, Croatia.

A Capela (A)

Associação de Investigação de Cuidados de Suporte em Oncologia (AICSO), Portugal; Centro Hospitalar Vila Nova de Gaia, Espinho, Portugal.

J Silva (J)

Associação de Investigação de Cuidados de Suporte em Oncologia (AICSO), Portugal; Centro Hospitalar Vila Nova de Gaia, Espinho, Portugal.

M J Hjermstad (MJ)

European Palliative Care Research Centre (PRC), Department of Oncology, Oslo University Hospital and Institute of Clinical Medicine of University of Oslo, Oslo, Norway; Regional Advisory Unit for Palliative Care, Department of Oncology, Oslo University Hospital, Oslo, Norway.

T Urbanic Purkart (TU)

Department of Neurology and Neuroradiology, Vascular and Interventional Radiology, Medical University of Graz, Austria.

C Seidel (C)

Department of Radiation Oncology, University of Leipzig Medical Center, Leipzig, Germany.

N Talhi (N)

Department of Radiation Oncology, University of Leipzig Medical Center, Leipzig, Germany.

J Pichler (J)

Institut für Innere Medizin mit Neuroonkologie, Kepler Universitätsklinikum GmbH, Linz, Austria.

I Höllmüller (I)

Institut für Innere Medizin mit Neuroonkologie, Kepler Universitätsklinikum GmbH, Linz, Austria.

L Brown (L)

John Eastwood Hospice, Sutton-in-Ashfield, United Kingdom.

M Hand (M)

John Eastwood Hospice, Sutton-in-Ashfield, United Kingdom.

M Klein (M)

Cancer Center Amsterdam, Brain Tumor Center, Amsterdam, the Netherlands; Department of Medical Psychology, Amsterdam University Medical Centers (Location VUmc), Amsterdam, the Netherlands.

N K Aaronson (NK)

Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

B M J Uitdehaag (BMJ)

Department of Neurology & Brain Tumor Center Amsterdam, Amsterdam University Medical Centers (Location VUmc), Amsterdam, the Netherlands.

M J B Taphoorn (MJB)

Department of Neurology, Haaglanden Medical Center, The Hague, the Netherlands; Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: m.j.b.taphoorn@lumc.nl.

L Dirven (L)

Department of Neurology, Haaglanden Medical Center, The Hague, the Netherlands; Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.

Classifications MeSH